Evaluation of the effects of Calcitriol on acute kidney injury

Evaluation of the efficacy of Calcitriol treatment on acute kidney injury improvement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016022326716N1

Enrollment

122

Registered

2016-07-30

Start date

2015-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute kidney injury. acute renal impairment

Interventions

Intervention 1: 0.25 mg of calcitriol was given to the patients in intervention group on a daily basis since AKI diagnosis up to recovery or for 3 months since the diagnosis of AKI if recovery did no

Treatment - Drugs

0.25 mg of calcitriol was given to the patients in intervention group on a daily basis since AKI diagnosis up to recovery or for 3 months since the diagnosis of AKI if recovery did not happen

One capsule filled with starch was given to the patients in control group on a daily basis since AKI diagnosis up to recovery or for 3 months since the diagnosis of AKI if recovery did not happen

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age:18 years old or more; voluntary participation in the study?.admission in ordinary wards, CCU, ICU Exclusion criteria: Using vitamin D or its derivatives at the time of study initiation;the type of malignancies that lead to calcium level more than 10.5mg/dl;serum calcium level more than 10.5mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Maximum creatinin level. Timepoint: daily. Method of measurement: blood sampling.;Number of dialysis sessions during admission. Timepoint: daily. Method of measurement: researcher made checklist.;Admission duration. Timepoint: daily. Method of measurement: researcher made checklist.;Recovery duration. Timepoint: daily. Method of measurement: researcher made checklist.;Becoming CKD. Timepoint: monthly up to three months. Method of measurement: serum creatinin measurement.;Mortality rate. Timepoint: three months maximum. Method of measurement: researcher made checklist.	—

Measure

Time frame

Maximum creatinin level. Timepoint: daily. Method of measurement: blood sampling.;Number of dialysis sessions during admission. Timepoint: daily. Method of measurement: researcher made checklist.;Admission duration. Timepoint: daily. Method of measurement: researcher made checklist.;Recovery duration. Timepoint: daily. Method of measurement: researcher made checklist.;Becoming CKD. Timepoint: monthly up to three months. Method of measurement: serum creatinin measurement.;Mortality rate. Timepoint: three months maximum. Method of measurement: researcher made checklist.

—

Secondary

Measure	Time frame
Hyperphosphatemia. Timepoint: during three months. Method of measurement: blood sampling.;Hypercalcemia. Timepoint: during three months. Method of measurement: blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrak Montazeran

ARAK University of Medical Sciences

m.montazeran@arakmu.ac.ir+98 86 3417 3630

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026